# NCT03860272 (NCT03860272)

> Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

No report yet. It can be ordered.

- Drugs tested: botensilimab plus balstilimab; botensilimab
- Indication: advanced cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03860272
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Agenus Inc.
- Conditions: Advanced Cancer; Angiosarcoma; Colorectal Cancer Without Liver Metastases; Endometrial Cancer; Fibrolamellar Carcinoma; Non-small-cell Lung Cancer; Ovarian Cancer; Prostate Cancer
- Interventions: Botensilimab; Balstilimab
- Enrollment: 499
- Primary outcome: Incidence Of Treatment-emergent Adverse Events (TEAEs)
- Primary outcome: DLT Of Botensilimab
- Primary outcome: RP2D Of Botensilimab

## Indexed commentary on NCT03860272 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03860272